Peptide-based gene delivery

Ram I. Mahato, Oscar D. Monera, Louis C. Smith, Alain Rolland

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

To achieve effective plasmid-based gene therapy, the control of cellular access and uptake, intracellular trafficking and nuclear retention of plasmids must be achieved. Inefficient endosomal release, cytoplasmic transport and nuclear entry of plasmids are amongst some of the key limiting factors in the use of plasmids for effective gene therapy. A number of non- viral gene delivery systems have been designed to overcome these limiting factors. The most common approach to protect and control plasmid distribution is to complex plasmids with cationic lipids or polymers through electrostatic interactions. Endosomal release of plasmids can be achieved, for instance, by using pH-sensitive lipids, inactivated viral particles, endosomolytic peptides and polymers. Among the least explored gene delivery systems are those that consist mainly of synthetic, short peptides. Peptides can be incorporated into multicomponent gene delivery complexes for specific purposes, such as for DNA condensation, cell-specific targeting, endosomolysis or nuclear transport. The aims of this review are to: (i) explore the conceptual and experimental aspects of peptide-DNA interactions; (ii) critically assess the possible use of peptides for efficient gene transfer; and (iii) present an overview on the use of peptides to enhance the effectiveness of other gene delivery systems. On balance, peptide-based gene delivery systems appear to have a significant potential as commercially viable gene delivery products.

Original languageEnglish (US)
Pages (from-to)226-243
Number of pages18
JournalCurrent Opinion in Molecular Therapeutics
Volume1
Issue number2
StatePublished - Apr 1 1999

Fingerprint

Plasmids
Gene Transfer Techniques
Peptides
Genes
Cell Nucleus Active Transport
Genetic Therapy
Polymers
Lipids
Viral Genes
DNA
Static Electricity
Virion

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

Mahato, R. I., Monera, O. D., Smith, L. C., & Rolland, A. (1999). Peptide-based gene delivery. Current Opinion in Molecular Therapeutics, 1(2), 226-243.

Peptide-based gene delivery. / Mahato, Ram I.; Monera, Oscar D.; Smith, Louis C.; Rolland, Alain.

In: Current Opinion in Molecular Therapeutics, Vol. 1, No. 2, 01.04.1999, p. 226-243.

Research output: Contribution to journalArticle

Mahato, RI, Monera, OD, Smith, LC & Rolland, A 1999, 'Peptide-based gene delivery', Current Opinion in Molecular Therapeutics, vol. 1, no. 2, pp. 226-243.
Mahato RI, Monera OD, Smith LC, Rolland A. Peptide-based gene delivery. Current Opinion in Molecular Therapeutics. 1999 Apr 1;1(2):226-243.
Mahato, Ram I. ; Monera, Oscar D. ; Smith, Louis C. ; Rolland, Alain. / Peptide-based gene delivery. In: Current Opinion in Molecular Therapeutics. 1999 ; Vol. 1, No. 2. pp. 226-243.
@article{6168ea7743a743d5a2076514a21e81d3,
title = "Peptide-based gene delivery",
abstract = "To achieve effective plasmid-based gene therapy, the control of cellular access and uptake, intracellular trafficking and nuclear retention of plasmids must be achieved. Inefficient endosomal release, cytoplasmic transport and nuclear entry of plasmids are amongst some of the key limiting factors in the use of plasmids for effective gene therapy. A number of non- viral gene delivery systems have been designed to overcome these limiting factors. The most common approach to protect and control plasmid distribution is to complex plasmids with cationic lipids or polymers through electrostatic interactions. Endosomal release of plasmids can be achieved, for instance, by using pH-sensitive lipids, inactivated viral particles, endosomolytic peptides and polymers. Among the least explored gene delivery systems are those that consist mainly of synthetic, short peptides. Peptides can be incorporated into multicomponent gene delivery complexes for specific purposes, such as for DNA condensation, cell-specific targeting, endosomolysis or nuclear transport. The aims of this review are to: (i) explore the conceptual and experimental aspects of peptide-DNA interactions; (ii) critically assess the possible use of peptides for efficient gene transfer; and (iii) present an overview on the use of peptides to enhance the effectiveness of other gene delivery systems. On balance, peptide-based gene delivery systems appear to have a significant potential as commercially viable gene delivery products.",
author = "Mahato, {Ram I.} and Monera, {Oscar D.} and Smith, {Louis C.} and Alain Rolland",
year = "1999",
month = "4",
day = "1",
language = "English (US)",
volume = "1",
pages = "226--243",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "2",

}

TY - JOUR

T1 - Peptide-based gene delivery

AU - Mahato, Ram I.

AU - Monera, Oscar D.

AU - Smith, Louis C.

AU - Rolland, Alain

PY - 1999/4/1

Y1 - 1999/4/1

N2 - To achieve effective plasmid-based gene therapy, the control of cellular access and uptake, intracellular trafficking and nuclear retention of plasmids must be achieved. Inefficient endosomal release, cytoplasmic transport and nuclear entry of plasmids are amongst some of the key limiting factors in the use of plasmids for effective gene therapy. A number of non- viral gene delivery systems have been designed to overcome these limiting factors. The most common approach to protect and control plasmid distribution is to complex plasmids with cationic lipids or polymers through electrostatic interactions. Endosomal release of plasmids can be achieved, for instance, by using pH-sensitive lipids, inactivated viral particles, endosomolytic peptides and polymers. Among the least explored gene delivery systems are those that consist mainly of synthetic, short peptides. Peptides can be incorporated into multicomponent gene delivery complexes for specific purposes, such as for DNA condensation, cell-specific targeting, endosomolysis or nuclear transport. The aims of this review are to: (i) explore the conceptual and experimental aspects of peptide-DNA interactions; (ii) critically assess the possible use of peptides for efficient gene transfer; and (iii) present an overview on the use of peptides to enhance the effectiveness of other gene delivery systems. On balance, peptide-based gene delivery systems appear to have a significant potential as commercially viable gene delivery products.

AB - To achieve effective plasmid-based gene therapy, the control of cellular access and uptake, intracellular trafficking and nuclear retention of plasmids must be achieved. Inefficient endosomal release, cytoplasmic transport and nuclear entry of plasmids are amongst some of the key limiting factors in the use of plasmids for effective gene therapy. A number of non- viral gene delivery systems have been designed to overcome these limiting factors. The most common approach to protect and control plasmid distribution is to complex plasmids with cationic lipids or polymers through electrostatic interactions. Endosomal release of plasmids can be achieved, for instance, by using pH-sensitive lipids, inactivated viral particles, endosomolytic peptides and polymers. Among the least explored gene delivery systems are those that consist mainly of synthetic, short peptides. Peptides can be incorporated into multicomponent gene delivery complexes for specific purposes, such as for DNA condensation, cell-specific targeting, endosomolysis or nuclear transport. The aims of this review are to: (i) explore the conceptual and experimental aspects of peptide-DNA interactions; (ii) critically assess the possible use of peptides for efficient gene transfer; and (iii) present an overview on the use of peptides to enhance the effectiveness of other gene delivery systems. On balance, peptide-based gene delivery systems appear to have a significant potential as commercially viable gene delivery products.

UR - http://www.scopus.com/inward/record.url?scp=0033042567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033042567&partnerID=8YFLogxK

M3 - Article

C2 - 11715946

AN - SCOPUS:0033042567

VL - 1

SP - 226

EP - 243

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 2

ER -